

SCHEDULE OF PHARMACEUTICAL BENEFITS EFFECTIVE 1 FEBRUARY 2024 ERRATUM

(1) This Erratum removes the new listing for **Cabotegravir** in the 1 February 2024 Schedule. This listing is no longer proceeding for 1 February 2024.

General Pharmaceutical Benefits

▪ **CABOTEGRAVIR**

Note PrEP users who explain they have had suboptimal adherence but are willing and suitable to continue on tenofovir disoproxil and emtricitabine as PrEP, should be offered additional adherence education.

Note No increase in the maximum quantity or number of units may be authorised.

Note No increase in the maximum number of repeats may be authorised.

Note Special Pricing Arrangements apply.

Authority required (STREAMLINED)


14827

Pre-exposure prophylaxis (PrEP) against human immunodeficiency virus (HIV) infection

Clinical criteria:

- Patient must have a negative HIV test result prior to having the latest PBS-subsidised prescription issued, in accordance with applicable PrEP guidelines, **AND**
- Patient must be at the time of initiation with this drug, either: i) contraindicated to treatment with tenofovir disoproxil and emtricitabine, ii) intolerant to treatment with tenofovir disoproxil and emtricitabine; OR
- Patient must have demonstrated/is highly likely to demonstrate, suboptimal adherence to tenofovir disoproxil and emtricitabine as PrEP such that the efficacy of tenofovir disoproxil and emtricitabine would have been/would be compromised.

cabotegravir 600 mg/3 mL modified release injection, 3 mL vial

13827R	Max. Qty Packs	No. of Rpts	Premium \$	DPMQ \$	MRVSN \$	Brand Name and Manufacturer
	1	1406.74	31.60	Apretude [VI]